Malignant Reproductive System Neoplasm
Malignant reproductive system neoplasms most frequently harbor alterations in TP53, PTEN, PIK3CA, ARID1A, and KRAS .
TP53 Mutation, TP53 Missense, TP53 c.217-c.1178 Missense, PIK3CA Mutation, and PTEN Mutation are the most common alterations in malignant reproductive system neoplasm .
There are 6 clinical trials for malignant reproductive system neoplasm, of which 6 are open and 0 are completed or closed. Of the trials that contain malignant reproductive system neoplasm as an inclusion criterion, 2 are phase 1 (2 open) and 4 are phase 2 (4 open).
Ipilimumab, nivolumab, and aldesleukin are the most common interventions in malignant reproductive system neoplasm clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.